Hysteroscopic Myomectomy for Uterine Fibroids

Hysteroscopic myomectomy is a minimally invasive surgical procedure that removes fibroids (leiomyomas) from inside the uterus through the cervix, with no abdominal incisions. It is the standard treatment for submucosal fibroids, the type that grow into or just beneath the uterine lining, and it reliably improves heavy menstrual bleeding in roughly nine out of ten patients who undergo it. But the procedure is more nuanced than that summary suggests, with outcomes that depend heavily on the fibroid’s size, depth, and classification, the equipment the surgeon uses, and whether any preoperative treatment is given first.

Which Fibroids Qualify

Not every fibroid can be reached through a hysteroscope. The procedure targets submucosal fibroids, which are classified by how much of their mass sits inside the uterine cavity versus buried in the muscular wall. The International Federation of Gynecology and Obstetrics (FIGO) system assigns them types 0 through 2. A type 0 fibroid is entirely within the cavity, sitting on a stalk. A type 1 is mostly inside but with less than half its volume embedded in the wall. A type 2 has more than half its mass within the wall and only a portion protruding into the cavity. Since 2018, the classification has also included type 3 fibroids, which develop within the muscle layer but push against the lining enough to distort it; these are now grouped with submucosal leiomyomas and can sometimes be distinguished from type 2 fibroids during hysteroscopy by using the lowest possible intrauterine pressure for visualization.¹

The classification matters because it predicts how easy the surgery will be. A study of over 300 hysteroscopic myomectomies found that having a type 0 fibroid roughly doubled the likelihood of completing the removal in a single procedure, while each additional millimeter of fibroid diameter reduced that likelihood.² Type 2 fibroids, with their deeper intramural component, are the most technically challenging and sometimes require staged removal or preoperative shrinkage strategies.

Surgical Techniques and Equipment

The traditional approach uses a resectoscope, a rigid instrument that shaves the fibroid in thin slices using an electrified wire loop. This technique has been the workhorse of hysteroscopic myomectomy since the late 1970s, when Neuwirth first described transcervical resection of submucous fibroids under direct vision.³ Earlier resectoscopes used monopolar energy, which required electrolyte-free distension fluids and carried a higher risk of dangerous electrolyte imbalances. Modern bipolar resectoscopes use saline, which is far safer in that regard.

The newer alternative is mechanical hysteroscopic tissue removal, sometimes called hysteroscopic morcellation. Devices like the MyoSure and the Integrated Bigatti Shaver cut and suction tissue fragments simultaneously, which means the surgeon does not have to repeatedly pull the instrument out to remove chips of fibroid. This reduces operating time and the volume of distension fluid needed to complete the procedure.⁴ A randomized trial comparing the two methods for type 0 and type 1 fibroids found that morcellation had a median operating time about four minutes shorter than bipolar resection, with operative time reduced by roughly a quarter after adjusting for fibroid size.⁵ For type 0 and type 1 fibroids and endometrial polyps, the time advantage of morcellation devices held up across another comparative study, though the difference disappeared for type 2 fibroids, where both approaches took similarly long.⁶

A third approach avoids electrosurgery entirely. Cold enucleation uses mechanical instruments to shell the fibroid out of the wall in one piece, then extracts it through a double-lumen cannula. This eliminates thermal injury to the surrounding muscle and avoids the need for electrolyte-free fluids, which means some of the most worrisome complications of the procedure become essentially irrelevant.⁷ It is particularly useful for type 2 fibroids with deep intramural components, where electrosurgery risks damaging surrounding tissue.

Preoperative Shrinkage

For large submucosal fibroids, surgeons sometimes prescribe hormonal treatment beforehand to shrink the fibroid and make removal easier. GnRH agonists (drugs like leuprolide that temporarily suppress estrogen) are the most common choice. A randomized multicenter trial showed they shortened operative time by about five minutes and reduced fluid absorption by roughly a third compared to operating without pretreatment.⁸ In patients with large submucosal fibroids, GnRH agonist pretreatment shrank fibroid volume by more than half and cut both operating time and the amount of distension fluid used.⁹

That said, the evidence for routine use is not overwhelming. A systematic review and meta-analysis concluded that while GnRH analogues shortened operating time by about five minutes and reduced fluid deficit, they did not significantly improve the chances of completing the surgery in one sitting. The authors found insufficient evidence to recommend their routine use before hysteroscopic myomectomy.¹⁰ The drugs also come with menopausal side effects and can make the fibroid boundary harder to identify at surgery. Most surgeons reserve them for fibroids larger than about 3 to 4 centimeters or for type 2 fibroids that would otherwise be difficult to remove in one procedure.

A newer preoperative option is high-intensity focused ultrasound (HIFU), which heats and destroys part of the fibroid noninvasively. In one study comparing HIFU to GnRH agonists before hysteroscopic myomectomy of large type 2 fibroids, HIFU downgraded a third of fibroids all the way to type 0, while GnRH agonists achieved only type 1 downgrades. Both approaches led to similar rates of complete single-step removal and similar complication rates.¹¹

Fluid Management and Its Risks

The uterine cavity is a potential space that must be inflated with fluid during hysteroscopy so the surgeon can see and work. This irrigation fluid is under pressure, and the body absorbs some of it through the uterine lining, the fallopian tubes, and especially through blood vessels that get opened when fibroid tissue is cut. The risk of absorption climbs with longer procedures, larger fibroids, and deeper intramural resection.¹²

If too much fluid enters the bloodstream, the consequences can be severe: fluid overload straining the heart, dangerous drops in blood sodium, pulmonary edema, or in extreme cases, cerebral edema and death. The type of fluid matters. Monopolar electrosurgery requires non-ionic (electrolyte-free) solutions, which cause dilutional hyponatremia faster. Absorbing as little as 500 milliliters of these solutions can trigger problems, and surgery should stop at a deficit of 1,000 milliliters. Bipolar instruments and morcellators use normal saline, which is safer, but even saline absorption becomes dangerous above about 1,500 milliliters.¹³ For older patients or those with heart or kidney disease, the safe threshold is lower. Automated fluid management systems that track input and output in real time are strongly recommended and widely considered the standard of care.

Intrauterine Adhesions After Surgery

One of the most talked-about complications of hysteroscopic myomectomy is the formation of scar tissue inside the uterus afterward, known as intrauterine adhesions or synechiae. When the raw surfaces left after fibroid removal heal, opposing walls of the uterus can stick together. This is especially common after removal of large fibroids. In one study, about 9% of patients who had no adhesions before surgery developed new ones after hysteroscopic myomectomy, while patients who already had adhesions and underwent simultaneous lysis saw a recurrence rate above 50%.¹⁴

Anti-adhesion barriers are increasingly used to reduce this risk. A study examining hyaluronic acid gel applied after removal of large submucosal fibroids found that the adhesion rate dropped from about 31% in the control group to around 6% in the gel group, and moderate or severe adhesions occurred only in untreated patients.¹⁵ Many surgeons also schedule a follow-up diagnostic hysteroscopy a few weeks after the procedure to identify and lyse any early adhesions before they mature.

Anesthesia and Setting

Hysteroscopic myomectomy has traditionally been performed under general anesthesia in an operating room, but there is growing interest in doing it under procedural sedation and analgesia instead. A multicenter randomized trial compared the two approaches for type 0 and type 1 fibroids. Procedural sedation did not meet the statistical bar for noninferiority in terms of completeness of resection, meaning the study could not definitively say sedation was just as good at getting the whole fibroid out. However, clinical outcomes and quality of life were similar between the groups, and the sedation group had shorter hospital stays.¹⁶ The upshot: for smaller, more accessible fibroids, procedural sedation is a safe option that lets patients go home sooner, but general anesthesia remains the default when fibroids are larger or deeper.

Symptom Relief and Quality of Life

The primary reason most people undergo hysteroscopic myomectomy is heavy or prolonged menstrual bleeding, and the procedure works well for this. A study using bipolar resection with at least one year of follow-up reported improved menstrual symptoms in 91% of patients, with 86% expressing overall satisfaction.¹⁷ Longer-term data confirm that the procedure delivers satisfactory control of heavy bleeding with limited recurrence.¹⁸

Beyond bleeding control, hysteroscopic myomectomy improves broader quality of life. A comparison of hysteroscopic management versus hysterectomy found that health-related quality of life was significantly better in the hysteroscopic group at both short-term and long-term follow-up.¹⁹ A randomized trial comparing hysteroscopic morcellation to medical management alone showed substantially greater improvements in symptom severity, self-consciousness, and concern scores at six months or more for the surgical group.²⁰

Fertility After Hysteroscopic Myomectomy

Many patients are referred for this procedure specifically because submucosal fibroids may be affecting their ability to conceive or carry a pregnancy. The data here are encouraging but less clear-cut than the bleeding data. A multicenter retrospective study found a spontaneous pregnancy rate of about 28% after fertility-enhancing hysteroscopic surgery overall, but the rate was significantly higher among women who had fibroid resection compared to those who had septal surgery. Patients who had failed IVF before the procedure saw a 50% success rate with IVF afterward. After myomectomy specifically, there were more term pregnancies and fewer miscarriages than after septal correction.²¹

Longer-term studies have been less enthusiastic. One found that while heavy bleeding was reliably controlled, the benefit for infertility was “less impressive.”²² The challenge is that infertility is multifactorial, and removing a fibroid only helps when the fibroid was actually a contributing factor. For patients with otherwise unexplained infertility and a submucosal fibroid distorting the cavity, removal is widely recommended. For those with other concurrent causes of infertility, the benefit is harder to isolate.

An important reassurance for people planning pregnancy afterward: because hysteroscopic myomectomy does not cut through the full thickness of the uterine wall, it generally does not compromise the structural integrity of the uterus the way an abdominal myomectomy might. A systematic review of labor after myomectomy found an overall uterine rupture risk of about 0.5%, but this figure includes abdominal and laparoscopic myomectomies, where the wall is cut deeply. After a purely hysteroscopic approach for a submucosal fibroid, the risk is thought to be lower, and most patients are cleared for vaginal delivery without the automatic cesarean section recommendation that often follows open myomectomy.²³

Recurrence Over Time

Fibroids can come back, whether from regrowth of incompletely removed tissue or from new fibroids forming elsewhere. A five-year follow-up study of patients who had mechanical morcellation found no recurrences at one year. By the second year, about 1% had recurrent fibroids, and the estimated rate with full follow-up was projected to be around 5 to 6%.²⁴ A longer-term study with an average follow-up of about seven years reported symptomatic recurrence in roughly 29% of patients treated with morcellation and about 39% treated with bipolar resection, though this difference was not statistically significant. The cumulative rate of eventual hysterectomy was similar between the two techniques, at about 16% and 22% respectively.²⁵ When recurrence does happen, repeated hysteroscopic treatment is the most common management approach, so the initial surgery does not necessarily lock anyone into more invasive options later.

Ultrasound Guidance During Surgery

For fibroids that sit deep in the wall, particularly type 2 fibroids, one of the main fears during surgery is perforating the uterus by cutting too deep. Real-time ultrasound monitoring during the procedure helps the surgeon see exactly how much wall remains between the resection and the outer surface. Evidence suggests that intraoperative ultrasound significantly reduces the risk of perforation for type 2 fibroids and makes it more likely that the entire fibroid can be removed in a single procedure.²⁶ In one series of patients with type 1 and type 2 fibroids operated under ultrasound guidance, no perforations occurred and all fibroids were removed completely.²⁷

How It Compares to Uterine Artery Embolization

Uterine artery embolization (UAE) is a radiology-based procedure that shrinks fibroids by cutting off their blood supply. It avoids surgery entirely and has a shorter hospital stay. But the trade-off shows up in the long run. A meta-analysis found that reintervention rates were more than twice as high with UAE compared to myomectomy.²⁸ A second meta-analysis confirmed this pattern and added that women who had UAE were at significantly greater risk of eventually needing a hysterectomy at one, two, and four years of follow-up, with odds roughly two to four times higher than after myomectomy.²⁹ UAE is a reasonable choice for patients who are not surgical candidates or who have completed childbearing and prioritize a shorter initial recovery. For people who want to preserve fertility or minimize the chance of needing a second procedure, myomectomy has the stronger evidence base.

The Rare but Serious Question of Sarcoma

One worry that haunts all fibroid surgery is the possibility that what looks like a benign fibroid on imaging is actually a uterine sarcoma, a rare cancer. This concern became especially prominent after the FDA restricted the use of power morcellators for laparoscopic surgery in 2014. For hysteroscopic myomectomy specifically, the numbers are small but worth understanding. A large ten-year series found the incidence of uterine sarcoma in patients undergoing surgery for presumed benign fibroids was about 1 in 335.³⁰ Interestingly, a study examining prevalence by surgical route found the highest rate of undiagnosed leiomyosarcoma among women who had hysteroscopic myomectomy, at roughly 1 in 116 for women under 50.³¹ A European survey reported a somewhat lower figure of about 0.07% for hysteroscopic cases.³²

These numbers are highly variable and depend on the study population, referral patterns, and how aggressively pathology is reviewed. The important takeaway is that all tissue removed during hysteroscopic myomectomy should be sent for histological examination. Preoperative imaging and clinical features can raise suspicion, but no imaging technique reliably distinguishes a benign fibroid from a sarcoma before surgery. Rapid growth of a presumed fibroid, especially in postmenopausal women, warrants extra caution and discussion of the possibility before proceeding.